Pelvic inflammatory disease in intrauterine device users

European Journal of Contraception and Reproductive Health Care

Volumn 1, Issue 3, 1996, Pages 237-243

  Beerthuizen, R J C M ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b Streekziekenhuis Koningin Beatrix ^*  (Netherlands)

Author keywords

Intrauterine device; Pelvic inflammatory disease; Sexually transmitted disease

Indexed keywords

AGE DISTRIBUTION; FEMALE; HUMAN; INCIDENCE; INTRAUTERINE CONTRACEPTIVE DEVICE; MARRIAGE; PELVIC INFLAMMATORY DISEASE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK; RISK FACTOR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE;

AGE DISTRIBUTION; FEMALE; HUMANS; INCIDENCE; INTRAUTERINE DEVICES; MARITAL STATUS; PELVIC INFLAMMATORY DISEASE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES;

EID: 0030223340     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189609150665     Document Type: Article

References (56)

1. Reist A. Die gefahren der zur Konzeptionsverhütung intrauterm eingeführten sogenannten Sterilette oder Obturatoren, sowie des Fructuletts von Nassauer. Schweiz Med Wschr 1925; 5: 650-7
2. Draper JW, Studdiford WE. Report of a case of actinomycosis of the tubes and ovaries. Am J Obstet Gynecol 1926; 11: 603-8
3. Tietze K. Sieben Fälle schwerster Schädigung durch Intrauterinpessare. (Ein Fall von isolierter Genitalaktinomykose). Dtsch Med Wochenschr 1930; 56 (II): 1307-9
4. Jones HO. The cervical pessary - a menace to health and life. J Am Med Assoc 1932; 98: 1738
5. Pust. Ein brauchbarer Frauenschutz. Dtsch Med Wochenschr 1923; 29: 952-3
6. Tatum HJ. Intrauterine contraception. Am J Obstet Gynecol 1972; 112: 1000-23
7. Ota T. A study on the birth control with an intrauterine instrument. Jpn J Obstet Gynecol 1934; 17: 210-14
8. Sommer K. Konzeptionsverhütung durch Graefenbergring. Zbl Gynaek 1931; 55: 2547-9
9. Oppenheimer W. Prevention of pregnancy by the Graefenberg ring method. Am J Obstet Gynecol 1959; 78: 446-54
10. Ishihama A. Clinical studies on intrauterine rings, especially the present state of contraception in Japan and the experiences in the use of intrauterine rings. Yokohama Med Bull 1959; 10: 89-105
11. Tietze C, Lewit S, eds. Proceedings of the Conference of Intra-Uterine Contraceptive Devices, New York, April/May, 1962. Amsterdam: Excerpta Medica, 1962; International Congress Series No 54
12. Christian CD. Maternal deaths associated with an intrauterine device. Am J Obstet Gynecol 1974; 119: 441-4
13. Cates W, Ory HW, Rochat RW, et al. The intrauterine device and deaths from spontaneous abortion. N Engl J Med 1976; 295: 1155-9
14. Kahn HS, Tyler CW. An association between the Dalkon Shield and complicated pregnancies among women hospitalized for intrauterine contraception device-related disorders. Am J Obstet Gynecol 1976; 125: 83-6
15. World Health Organization. Mechanism of Action, Safety, and Efficacy of Intrauterine Devises. Technical Report Series 753. Geneva: WHO, 1987
16. Moors A, Thomas EJ. Pelvic inflammatory disease. Adv Obstet Gynaecol 1994; 9: 11-16
17. Westrom L, Bengtsson LP, Mardh P. The risk of pelvic inflammatory disease in women using intrauterine contraceptive devices as compared to non-users. Lancet 1976; 2: 221-4
18. Targum SD, Wright NH. Association of the intrauterine device and pelvic inflammatory disease: a retrospective pilot study. Am J Epidemiol 1974; 100: 262-71
19. Rivera R, Chi I, Farr G. The intrauterine device in the present and future. Curr Opin Obstet Gynecol 1993; 5: 829-32
20. Buchan H, Villard-Mackintosh L, Vessey M, et al. Epidemiology of pelvic inflammatory disease in parous women with special reference to the intrauterine device. Br J Obstet Gynaecol 1990; 97: 780-8
21. Mumford SD, Kessel E. Was the Dalkon Shield a safe and effective intrauterine device? The conflict between case-control and clinical trial study findings. Fertil Steril 1992; 57: 1151-76
22. Roy S, Azen C. A reanalysis of the Cu-7 intrauterine contraceptive device clinical trial and the incidence of pelvic inflammatory disease: a paradigm for assessing intrauterine contraceptive device safety. Am J Obstet Gynecol 1994; 170: 1606-16
23. Struthers BJ. Comparison of PID rates in parous and nulliparous women using copper IUDs. Summary of clinical studies. Adv Contracept 1990; 6: 257
24. Stacey CM, Munday PE, Taylor-Robinson D, et al. A longitudinal study of pelvic inflammatory disease. Br J Obstet Gynaecol 1992; 99: 994-9
25. Jossens MOR, Schachter RNJ, Sweet RL. Risk factors associated with pelvic inflammatory disease of differing microbial etiologies. Obstet Gynecol 1994; 83: 989-97
26. Morese KN, Peterson WF, Allen ST. Endometrial effects of an intrauterine contraceptive device. Obstet Gynecol 1966; 28: 323-8
27. Moyer DL, Mishell DR, Bell J. Reactions of human endometrium to the intrauterine device. Am J Obstet Gynecol 1970; 106: 799-806
28. Moyer DL, Mishell DR. Reactions of human endometrium to the intrauterine foreign body. II: Long-term effects on the endometrial histology and cytology. Am J Obstet Gynecol 1971; 111: 66-80
29. Beerthuizen RJCM, Van Wijck JAM, Eskes TKAB, et al. IUD and salpingitis: a prospective study of pathomorphological changes in the oviducts in IUD-users. Eur J Obstet Gynecol Reprod Biol 1982; 13: 31-41
30. Vanlancker M, Dierick AM, Thiery M, et al. Histologic and microbiologic findings in the Fallopian tubes of IUD users. Adv Contracept 1987; 3: 147-57
31. Wollen A, Sandvei R, Mork S, et al. In situ characterization of leukocytes in the Fallopian tube in women with or without an intrauterine contraceptive device. Acta Obstet Gynecol Scand 1994; 73: 103-12
32. Smith MR, Soderstrom B. Salpingitis: a frequent response to intrauterine contraception. J Reprod Med 1976; 16: 159-62
33. Tatuin HJ, Schmidt FH, Phillips D, et al. The Dalkon Shield controversy, structural and bacteriological studies of IUD tails. J Am Med Assoc 1975; 231: 711-17
34. Treimau K, Liksin L. IUDs - a new look. Population Report 1988; Series B No 5, B1-32
35. Buchman MI. A study of the IUDs with or without an extracervical appendage or tail. Fertil Steril 1979; 21: 348-55
36. Potts DM, Champion CB, Kozuh-Novak M, et al. IUDs and PID: a comparative trial of strings versus stringless devices. Adv Contracept 1991; 7: 231-40
37. Batar I, Lampe LG, Allonen H. Clinical experience with intrauterine devices inserted with and without tail. Int J Gynecol Obstet 1991; 36: 137-40
38. Parley TMM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339: 785-8
39. Mishell DR. The intrauterine device: a bacteriologic study of the endometrial cavity. Am J Obstet Gynecol 1966; 96: 119-26
40. Jackson R, Newton JR, Emens MJ, et al. Effects of chlorhexidine-coated intrauterine device on the bacteriology of the uterine cavity. Adv Contracept 1991; 7: 55-65
41. Sinei SKA, Schulz KF, Lamptey PR, et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol 1990; 97: 412-19
42. Lapido OA, Farr G, Otolorin E, et al. Prevention of IUD-related pelvic infection: the efficacy of prophylactic doxycycline at IUD insertion. Adv Contracept 1991; 7: 43-54
43. Walsh TL, Bernstein GS, Grimes DA, et al. Effect of prophylactic antibiotics on morbidity associated with IUD insertion: results of a pilot randomized controlled trial. Contraception 1994; 50: 319-27
44. Thompson SE, Washington AE. Epidemiology of sexually transmitted Chlamydia trachomatis infections. Epidemiol Rev 1983; 5: 96-123
45. Sprague D, Bullough C, Rashid S, Roberts S. Screening for and treating Chlamydia trachomatis and Neisseria gonorrhoeae before contraceptive use and subsequent pelvic inflammatory disease. Br J Fam Plann 1990; 16: 54-8
46. Denton GW. Chlorhexidine: a WHO essential drug. Lancet 1984; 1: 517
47. Keebler C, Chatwani A, Schwartz R. Actinomycosis infection associated with intrauterine contraceptive devices. Am J Obstet Gynecol 1983; 145: 596-9
48. Blohmer JU, Hufnagl HU, Kürten A, Bollmann R. Die Intra-uterinpessar-assoziierte genitale Aktinomykose. Fortsch Med 1994; 112; 305-7
49. Singh MM, Ingham HR, Wadehra V, et al. Endometrial culture in IUD users with actinomyces-like organisms (ALOs) on cervical smears. Br J Fam Plann 1989; 15: 3-6
50. Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 1995; 52: 269-76
51. Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device. 12-month report of a European multicenter study. Contraception 1984; 30: 443-56
52. Toivonen J, Lukkainen T, Allonen H. Protective effective of intrauterine release of levonorgestrel on pelvic infection. Three years comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 1991; 77: 261-4
53. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (nova-T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49: 56-72
54. UNDP, UNFPA and WHO Special Programme of Research, Development and Research Training in Human Reproduction. World Bank: IUD Research Group. The TCu380A and the frameless IUD 'The Flexigard®: interim three-year data from an international multicenter trial. Contraception 1995; 52: 77-83
55. Van Kets H, Vrijens M, Van Trappen Y, et al. The frameless GyneFix intrauterine implant: a major improvement in efficacy, expulsion and tolerance. Adv Contracept 1995; 11: 131-42
56. Toivonen J. Intrauterine contraceptive device and pelvic inflammatory disease. Ann Med 1993; 25: 171-3